CYP2C19基因多态性对精神分裂症患者丙戊酸血药浓度的影响

谢燕; 宋明芬; 章隆; 王玉文; 董介正; 施剑飞; 朱婉儿<sup>*</sup>

引用本文:	谢燕,宋明芬,章隆,王玉文,董介正,施剑飞,朱婉儿.CYP2C19基因多态性对精神分裂症患者丙戊酸血药浓度的影响[J].中国现代应用药学,2016,33(5):653-657.
	XIE Yan,SONG Mingfen,ZHANG Long,WANG Yuwen,DONG Jiezheng,SHI Jianfei,ZHU Waner.Effect of CYP2C19 Genetic Polymorphism on Blood Concentration of Valproic Acid in Schizophrenia[J].Chin J Mod Appl Pharm(中国现代应用药学),2016,33(5):653-657.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 2361次下载 1703次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
CYP2C19基因多态性对精神分裂症患者丙戊酸血药浓度的影响
谢燕^1,2, 宋明芬², 章隆³, 王玉文⁴, 董介正⁵, 施剑飞⁶, 朱婉儿¹
1.浙江大学医学部，杭州 310058;2.杭州市第七人民医院，杭州 310013;3.杭州市第七人民医院，杭州 310014;4.杭州市第七人民医院，杭州 310015;5.杭州市第七人民医院，杭州 310016;6.杭州市第七人民医院，杭州 310017

摘要:

目的研究CYP2C19基因多态性与精神分裂症患者心境稳定剂丙戊酸血药浓度的关系。方法选择奥氮平治疗且服用丙戊酸钠作为心境稳定剂的精神分裂症患者160例，采集血液，测定CYP2C19基因型以及丙戊酸血药浓度，比较各个基因型血药浓度的差异。结果 *2/*2型(122.06±41.30)mg·L^-1和*2/*3型(132.34±51.34)mg·L^-1患者丙戊酸血药浓度明显高于野生*1/*1型(79.41±25.14)mg·L^-1(P<0.05或P<0.01)；*1/*1、*1/*2和*1/*3型之间、*2/*2和*2/*3型之间血药浓度无统计学差异；PM型血药浓度(122.13±42.85)mg·L^-1与EM型(80.59±48.60)mg·L^-1比较，显著升高(P<0.05)。结论 *2/*2和*2/*3型CYP2C19患者，其血液丙戊酸浓度较高，该类患者服用丙戊酸作为精神分裂症心境稳定剂时，宜适当降低用药剂量。

关键词: 精神分裂症 CYP2C19基因多态性丙戊酸血药浓度

DOI：

分类号:R74

基金项目:浙江省自然科学基金(LQ13H090003)；杭州市科技发展计划项目重点专科专病科研攻关专项(20130733Q27、20130733Q26)；杭州市卫生科技计划重点项目(2014Z10)

Effect of CYP2C19 Genetic Polymorphism on Blood Concentration of Valproic Acid in Schizophrenia

XIE Yan^1,2, SONG Mingfen², ZHANG Long³, WANG Yuwen⁴, DONG Jiezheng⁵, SHI Jianfei⁶, ZHU Waner¹

1.Zhejiang University, School of Medicine, Hangzhou 310058, China;2.Hangzhou Seventh People’s Hospital, Hangzhou 310013, China;3.Hangzhou Seventh People’s Hospital, Hangzhou 310014, China;4.Hangzhou Seventh People’s Hospital, Hangzhou 310015, China;5.Hangzhou Seventh People’s Hospital, Hangzhou 310016, China;6.Hangzhou Seventh People’s Hospital, Hangzhou 310017, China

Abstract:

OBJECTIVE To study the relationship between CYP2C19 genetic polymorphism and blood concentration of mood stabilizer of valproic acid in schizophrenia patients. METHODS Schizophrenia patients treated with olanzapine and mood stabilizer of valproic acid were recruited based on the criteria of inclusion and exclusion. The blood samples were collected for the determinations of CYP2C19 genetic polymorphism and blood concentration of valproic acid. Then the blood concentration of valproic acid within the types of CYP2C19 genetic polymorphism was compared. RESULTS Blood concentration of valproic acid in the types of *2/*2 (122.06±41.30)mg·L^-1 and *2/*3 (132.34±51.34)mg·L^-1 were obviously higher than that of the wild *1/*1 type(79.41±25.14)mg·L^-1 (P<0.05, P<0.01). However, it was not significantly different in the types of *1/*1, *1/*2 and *1/*3 or in the types of *2/*2 and *2/*3. PM type (122.13±42.85)mg·L^-1 had obviously higher blood concentration than EM type(80.59±48.60)mg·L^-1(P<0.05). CONCLUSION The CYP2C19 types of *2/*2 and *2/*3 had high blood concentrations of valproic acid. These patients should receive a low dose of mood stabilizer of valproic acid in the treatment of schizophrenia.

Key words: schizophrenia CYP2C19 genetic polymorphism valproic acid blood concentration